
|Articles|August 26, 2019
ASRS 2019 Street Team: Peter K. Kaiser, MD
Author(s)OT Staff Reports
Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD.
Advertisement
Peter K. Kaiser, MD, shares the take-home message of his presentation, "Safety and Efficacy of Risuteganib in Intermediate Nonexudative Age-Related Macular Degeneration: First Time Results From a Phase 2 Study." Dr. Kaiser presented at the 2019 annual meeting of the American Society of Retina Specialists.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears IND for Complement Therapeutics’ CTx001 gene therapy in geographic atrophy
2
STAAR and Broadwood conflict over proposed Alcon merger continues
3
Ocular surface: Targeted therapies for a multifactorial problem
4
Finding your fit: Excimer lasers and early surgical practice
5